Biotech Valneva eyes growth inflection with Covid vaccine
CEO Thomas Lingelbach confident of European approval, but shuns 'pandemic stock' label.
Singapore
FRENCH biotech Valneva, a manufacturer of vaccines for travellers, was once a sleepy stock, with a market capitalisation of just 236.8 million euros (S$351.8 million) in end-2019. But entering the Covid-19 vaccine race has swept it into the public eye.
In 2020, Valneva unveiled plans to develop a Covid-19 vaccine based on the more mature non-mRNA technology. It has since faced many ups and downs, from positive trial results and emergency approval in Bahrain, to a cancelled contract with the United Kingdom.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Asia: Stocks mixed after Wall Street, Europe retreat from records
Mapletree closes second Japan logistics development fund; expects 110 billion yen AUM
Dolce & Gabbana metaverse fashion offering leaves shopper fuming
Microsoft offers cloud customers AMD alternative to Nvidia AI processors
CEO of fallen Eagle Hospitality Trust seeks to contest four disclosure-related criminal charges
Crypto boom, erratic rain spark outages in Laos, Asia’s clean power export hub